The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INTS | -83.28% | N/A | N/A | -91% |
| S&P | +18.54% | +92.9% | +14.04% | +52% |
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | -16.7% |
| Market Cap | $8.00M | -88.1% |
| Market Cap / Employee | $0.50M | 0.0% |
| Employees | 16 | -5.9% |
| Net Income | -$2.54M | 49.0% |
| EBITDA | -$2.70M | 46.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.22M | -31.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.10M | -23.4% |
| Short Term Debt | $0.03M | 11.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -191.80% | -79.7% |
| Return On Invested Capital | -215.42% | -93.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.46M | 41.7% |
| Operating Free Cash Flow | -$2.46M | 41.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.80 | 8.78 | 10.21 | 14.03 | 103.03% |
| Price to Tangible Book Value | 9.80 | 8.78 | 10.21 | 14.03 | 103.03% |
| Enterprise Value to EBITDA | -14.06 | -7.29 | -8.59 | -1.37 | -88.62% |
| Return on Equity | -174.0% | -202.3% | -298.6% | -334.1% | 126.94% |
| Total Debt | $0.15M | $0.14M | $0.13M | $0.13M | -17.22% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
